Cargando…

Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer

PURPOSE: To evaluate the dynamics of early serum tumour markers (STMs) and the neutrophil-to-lymphocyte ratio (NLR) to predict clinical efficacy and prognosis of advanced non-small-cell lung cancer (NSCLC) patients who received programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Yin, Cui, Yu, Li, Lin-lin, Guan, Ya-ping, Feng, Dong-feng, Yin, Bei-bei, Liang, Xue-feng, Yin, Jing, Jiang, Rui, Liang, Jing, Sun, Ya-hong, Wang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572022/ https://www.ncbi.nlm.nih.gov/pubmed/34754244 http://dx.doi.org/10.2147/CMAR.S329963

Ejemplares similares

Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade
por: Moschetta, Michele, et al.
Publicado: (2017)

Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer
por: Ruan, Dan-Yun, et al.
Publicado: (2021)

Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer
por: Hou, Yidan, et al.
Publicado: (2023)

Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy
por: Dharmapuri, Sirish, et al.
Publicado: (2020)

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
por: Chen, Chian-Wei, et al.
Publicado: (2023)

Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease
por: Feng, Jue-Rong, et al.
Publicado: (2017)

Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade
por: Han, Si-Chong, et al.
Publicado: (2023)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer
por: Gou, Miaomiao, et al.
Publicado: (2021)

Associations of the neutrophil to lymphocyte ratio with intracranial artery stenosis and ischemic stroke
por: Huang, Liang-Yu, et al.
Publicado: (2021)

Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Potential Predictors of Prognosis in Acute Ischemic Stroke
por: Chen, Cuiping, et al.
Publicado: (2021)

Programmed Death-Ligand 1 (PD-L1) Expression Associated with a High Neutrophil/Lymphocyte Ratio in Cholangiocarcinoma
por: Sangkhamanon, Sakkarn, et al.
Publicado: (2017)

Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung
por: Tashima, Yuko, et al.
Publicado: (2020)

Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study
por: Wilson, Julie K., et al.
Publicado: (2018)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
por: Qiao, Xin-wei, et al.
Publicado: (2020)

Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer
por: Zhang, Yan, et al.
Publicado: (2018)

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
por: Kitano, Atsuko, et al.
Publicado: (2017)

Predictive role of the monocyte-to-lymphocyte ratio in advanced hepatocellular carcinoma patients receiving anti-PD-1 therapy
por: Zhu, Zhen-Feng, et al.
Publicado: (2022)

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
por: Tsai, Jeng-Shiuan, et al.
Publicado: (2022)

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
por: Ameratunga, Malaka, et al.
Publicado: (2016)

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
por: Ayers, Kristin L., et al.
Publicado: (2021)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
por: Yajuk, Olga, et al.
Publicado: (2021)

Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis
por: Sun, Rui, et al.
Publicado: (2020)

Monocyte Distribution Width, Neutrophil-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio Improves Early Prediction for Sepsis at the Emergency
por: Hou, Sen-Kuang, et al.
Publicado: (2021)

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
por: Yuan, Keyu, et al.
Publicado: (2022)

PD-1 Expression Status on CD8+ Tumour Infiltrating Lymphocytes Associates With Survival in Cervical Cancer
por: Fan, Peiwen, et al.
Publicado: (2021)

Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential markers for ulcerative colitis: a retrospective study
por: Feng, Wan, et al.
Publicado: (2022)

A Composite Biomarker of Derived Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio Correlates With Outcomes in Advanced Gastric Cancer Patients Treated With Anti-PD-1 Antibodies
por: Pan, Yuting, et al.
Publicado: (2022)

Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma
por: Feng, Liang, et al.
Publicado: (2022)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy
por: Gao, Yiming, et al.
Publicado: (2022)

Neutrophil-to-lymphocyte ratio, obesity, and breast cancer risk in Chinese population
por: Fang, Qiong, et al.
Publicado: (2018)

The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non–Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors
por: Sun, Xiaoyan, et al.
Publicado: (2022)

The immunomodulatory effect of microglia on ECM neuroinflammation via the PD‐1/PD‐L1 pathway
por: Shen, Yan, et al.
Publicado: (2021)

Prognostic Significance of PD-L2 Expression in Association with Neutrophil-to-Lymphocyte Ratio in Urothelial Carcinoma of the Bladder
por: Hendri, Ahmad Zulfan, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as predictive markers in hepatoblastoma
por: Xie, Tan, et al.
Publicado: (2023)

Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value
por: He, Wen-Zhuo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sdm90j6gjorlss4tnsvecafaln